Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry

O. Perez,G. Nolan

DOI: https://doi.org/10.1038/nbt0202-155

IF: 46.9

2002-02-01

Nature Biotechnology

Abstract:

What problem does this paper attempt to address?

Condensation and salt-induced decondensation of DNA upon incorporation of a V-shaped luminescent [Ru2(bpy)4(mbpibH2)](4+).

Guilian Gan,Hui Chao,Xue-Ping Cai,Zhen-shen Jiang,Hong Li

DOI: https://doi.org/10.1016/j.jinorgbio.2013.07.041

IF: 4.336

2013-12-01

Journal of Inorganic Biochemistry

Abstract:
Color-dependent motion illusions in stationary images and their phenomenal dimorphism.

A. Kitaoka

IF: 1.695

Perception

Abstract:The color-dependent motion illusion in stationary images--a special type of the Fraser-Wilcox illusion--is introduced and discussed. The direction of illusory motion changes depending on whether the image is of high or low luminance and whether the room is bright or dark. This dimorphism of illusion was confirmed by surveys. It is suggested that two different spatial arrangements of color can produce the motion illusion. One is a spatial arrangement where long- and short-wavelength color regions sandwich a darker strip; the other is where the same color regions sandwich a brighter strip.
Statin-associated myasthenic weakness

Nath Pasutharnchat,Kammant Phanthumchinda

Abstract:Background: Statin-associated myasthenic weakness is uncommonly recognized. Since 2002, there have been 14 cases described in literatures. However, the underlying mechanism is still unknown. Case report: In 2007, a 50-year-old woman with generalized, limb predominated, myasthenia gravis (MG), whose MG status has been "minimal manifestation" for several years, developed moderately severe fluctuating bulbar weakness a few weeks after starting simvastatin 20 mg/day. Simvastatin was discontinued and dosage of cholinesterase inhibitor was temporarily increased. The symptoms resolved and she was back to her previous status in one month. In 2008, two weeks after re-challenge with simvastatin 10 mg/day, bulbar weakness re-occurred Antibody to acetylcholine receptors was measured 4.25 nmole/L. Serum creatine phosphokinase was normal. Electrophysiologic tests showed evidences of postsynaptic neuromuscular junction disorder without evidence of myopathy. The symptoms were again resolved after discontinuation of statin and temporarily increased dosage of cholinesterase inhibitor. She was back to previous status in two months. Hypercholesterolemia was then controlled with ezetimibe without any worsening in MG status. Conclusion: Because of the wide use of statins in clinical practice, physicians should be aware of this potential adverse effect. The incidence ofstatin-associated myasthenic weakness should be clearly investigated Challenge with other brands of statin or with reduced dosage is not beneficial in these patients. Non-pharmacological treatment and non-statin medication may be considered
[The Clinical and Muscular Pathological Features of Statin-Induced Myopathy].

Lingchao Meng,Yuanyuan Lu,Wei Zhang,Zhaoxia Wang,He Lyu,Yun Yuan

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2015.08.014

2015-01-01

Abstract:OBJECTIVE:To explore clinical and muscular pathological features of statin-induced myopathy.METHODS:Nine patients were enrolled in this study, who were diagnosed as statin-induced myopathy by muscle biopsy in Peking University First Hospital from April, 2012 to October, 2014. The clinical data and pathological findings were analyzed.RESULTS:The exposure time to statins varied from 4 days to 4 years in the total of 9 patients, 6 males and 3 females, with the average age of 63 ± 6 (55 to 74) years old. Three patients suffered from myalgia and 6 patients complained of weakness mainly at the proximal limbs, while no symptoms occured in 3 patients. Serum creatine kinase (CK) increased in all patients with the maximum value varied from 468 to 8 000 U/L. Serum myositis antibodies were tested in 7 patients and all were negative. Electromyogram was performed in six patients with myogenic damage found in 2 patients. MRI of bilateral thigh muscle was carried out in six patients with muscle edema and mild fatty infiltration found in 2 patients. All patients underwent skeletal muscle biopsy with histochemical and immunohistochemical staining. The main muscular pathological features were muscle fiber atrophy, necrosis, regeneration and increased lipid droplets. Ragged blue fiber, cytochrome C oxidase-negative muscle fibers and decreased NADH activity were observed in some patients. MHC-I expressed in the sarcolemma of muscle fibers at various levels. Mild C5b-9 staining was found in the endomysium, capillary and cytoplasm. Symptoms and the level of CK were improved in 7 patients after discontinuing statins or changing to another statin, while the immunosuppressive therapy were used in 2 patients and shown to be effective.CONCLUSIONS:Statin induced myopathy is self-limiting in most patients, with improvement after discontinuation of statins. Few patients with autoimmune necrotic myopathy need immunosuppressive therapy.
[Jaw orthodontic treatment from view point of the patient and parents].

S. Koller,H. Droschl

1976-06-01

Abstract:
[On the diagnosis of renovascular hypertonia].

W. Siegenthaler,P. Endres,P. Weidmann,M. Schönbeck,J. Möhring,E. Gysling,K. Baumann

DOI: https://doi.org/10.1055/S-0028-1105149

1968-04-19

Abstract:
Narrative Review: Statin-Related Myopathy

Tisha R. Joy

DOI: https://doi.org/10.7326/0003-4819-150-12-200906160-00009

IF: 39.2

2009-06-16

Annals of Internal Medicine

Abstract:Statin-related myopathy is a clinically important cause of statin intolerance and discontinuation. The spectrum of statin-related myopathy ranges from common but clinically benign myalgia to rare but life-threatening rhabdomyolysis. Observational studies suggest that myalgia can occur in up to 10% of persons prescribed statins, whereas rhabdomyolysis continues to be rare. The mechanisms of statin-related myopathy are unclear. Options for managing statin myopathy include statin switching, particularly to fluvastatin or low-dose rosuvastatin; nondaily dosing regimens; nonstatin alternatives, such as ezetimibe and bile acid-binding resins; and coenzyme Q10 supplementation. Few of these strategies have high-quality evidence supporting them. Because statin-related myopathy will probably become more common with greater numbers of persons starting high-dose statin therapy and the increasing stringency of low-density lipoprotein cholesterol level targets, research to better identify patients at risk for statin myopathy and to evaluate management strategies for statin-related myopathy is warranted.

medicine, general & internal
Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness

Maryam Barkhordarian,Mark Grijalva,Albert Lee,Amer Jarri,Anna Belyayeva,Simcha Weissman

DOI: https://doi.org/10.12659/AJCR.944261

2024-09-02

Abstract:BACKGROUND Statin-induced myopathy can present with symptoms ranging from mild myalgia to significant muscle weakness. Muscle-related adverse effects of statins have been very challenging in clinical practice and they necessitate high clinical suspicion. This case report highlights how statin-induced autoimmune myopathy often goes undiagnosed. CASE REPORT We present a 69-year-old man with a past medical history of coronary artery disease who presented with myalgia and progressive proximal muscle weakness for 2 months, with a creatinine kinase of 8323 U/L. Atorvastatin was held on admission and the patient received intravenous (IV) fluid as treatment for presumed rhabdomyolysis. Although CK was trending down, he did not show significant improvement in muscle weakness or myalgia. At this point, myositis was suspected, so a myositis panel including anti-HMG Co-A reductase antibody was ordered and he was started on IV steroids. Anti-HMG Co-A reductase antibody was positive, and the rest of myopathy workup was negative. Meanwhile, the patient's muscle weakness significantly improved with IV steroid. He was discharged on methylprednisolone with close outpatient rheumatology follow-up. CONCLUSIONS Muscle-related adverse effects of statins, including rhabdomyolysis and myopathy, can fail to respond to conservative management. It is crucial to identify and manage statin-induced autoimmune myopathy as a possible differential diagnosis in patients with muscle weakness and elevated CK while on statin therapy who do not respond to intravenous fluid alone.
Seizures in relation to head injury.

B. Desai,S. Whitman,R. Coonley-Hoganson,T. Coleman,Gayle Gabriel,J. Dell

DOI: https://doi.org/10.1016/S0196-0644(83)80294-7

IF: 6.762

1983-09-01

Annals of Emergency Medicine

Abstract:
The Role of Mitochondria in Statin-Induced Myopathy

Gavin Bell,Anastasia Thoma,Iain P. Hargreaves,Adam P. Lightfoot

DOI: https://doi.org/10.1007/s40264-024-01413-9

2024-03-17

Drug Safety

Abstract:Statins represent the primary therapy for combatting hypercholesterolemia and reducing mortality from cardiovascular events. Despite their pleiotropic effects in lowering cholesterol synthesis, circulating cholesterol, as well as reducing the risk of other systemic diseases, statins have adverse events in a small, but significant, population of treated patients. The most prominent of these adverse effects is statin-induced myopathy, which lacks precise definition but is characterised by elevations in the muscle enzyme creatine kinase alongside musculoskeletal complaints, including pain, weakness and fatigue. The exact aetiology of statin-induced myopathy remains to be elucidated, although impaired mitochondrial function is thought to be an important underlying cause. This may result from or be the consequence of several factors including statin-induced inhibition of coenzyme Q 10 (CoQ 10 ) biosynthesis, impaired Ca 2+ signalling and modified reactive oxygen species (ROS) generation. The purpose of this review article is to provide an update on the information available linking statin therapy with mitochondrial dysfunction and to outline any mechanistic insights, which may be beneficial in the future treatment of myopathic adverse events.

pharmacology & pharmacy,public, environmental & occupational health,toxicology
[Etiology and pathogenesis of primary hydrocele in children].

A. Meinel,H. Nemetschek-Gansler,V. Hočevar

1979-12-01

Abstract:The serous-wall of the typical, non-communicating, idiopathic hydrocele of the child presents with a lympho-static oedema, whose protein-containing fluid is pressed transmesothelially into the lumen. The cause must be seen in the lymph-drainage of the tunica vaginalis testis which follows the obliteration. The above described etiological-pathogenical concept gives the more or less empirical therapeutic-methods a rational basis.
Plasma statin concentrations do not correlate with statin-induced myalgia

M Ritvos,G Mombelli,M Ramste,M Laaperi,D Kauhanen,J Sinisalo,C Sirtori,P D Thompson,M P Dube,J C Tardif,R Laaksonen

DOI: https://doi.org/10.1093/eurheartj/ehae666.3296

IF: 39.3

2024-10-29

European Heart Journal

Abstract:Aims Statins are essential in cardiovascular prevention. Although well-tolerated, patient adherence is often suboptimal due to experienced musculoskeletal symptoms ranging from mild myalgia to rare life-threatening rhabdomyolysis. This study aimed to investigate the relationship between plasma concentrations of statin metabolites in patients experiencing myalgia without rhabdomyolysis. Methods and results Plasma concentrations of statin metabolites were quantitatively assessed using mass spectrometry across three case-control cohorts evaluating statin-induced myalgia. The analysis included a total of 373 patients from the MILANO study (N=85 with self -reported myalgia), the MONTREAL study (N=248 with clinically verified myalgia) and the STOMP study (N=40 with rechallenge-verified statin-induced myalgia). STOMP found no significant difference in the plasma concentrations of statin metabolites between statin naïve patients with myalgia (N=12) taking atorvastatin 80 mg daily and asymptomatic controls (N=28), including upon subsequent statin rechallenge. Both the MILANO and MONTREAL studies showed lower plasma concentrations of statin metabolites in patients with myalgias compared to controls. MILANO showed a significant difference in rosuvastatin lactone concentration in patients with myalgias compared to asymptomatic controls (P = 0.025). Similarly, MONTREAL showed significantly lower mean atorvastatin metabolite concentrations in affected patients versus controls (P values ranging from 0.0073 to 0.037). Atorvastatin dosages in MONTREAL ranged from 5 to 80 mg daily, the most frequent regimens being 20 mg (27% in cases; 24% in controls) and 40 mg (33% in cases; 37% in controls). Creatine kinase levels were measured in all cohorts and were not different between cases and controls. Conclusion Development of myalgias in patients with normal creatine kinase levels is not associated with higher statin metabolite plasma concentrations. Myalgias during statin therapy are not caused by pharmacokinetic abnormalities.

cardiac & cardiovascular systems
Anti-HMGCR myopathy mimicking facioscapulohumeral muscular dystrophy

Andreas Albert Braun,Monika Atiya,Katja Göhner,Tibor Hortobagyi,Tobias Burkhardt,Bettina Schreiner

DOI: https://doi.org/10.1515/med-2024-1033

2024-09-04

Abstract:Introduction: Statin use can lead to various muscle-related issues, including benign creatine kinase (CK) elevations, myalgias, toxic myopathies, rhabdomyolysis, and immune-mediated necrotizing myositis (IMNM), which primarily affects older males. IMNM presents with proximal muscle weakness, elevated CK levels, and specific antibodies. Case presentation: We describe a 72-year-old patient with muscle weakness persisting for over 3 years after statin therapy. Initially suspected to have a genetic disorder, further testing revealed elevated anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibodies, indicating immune-mediated myopathy. Despite the absence of inflammatory changes on biopsy, the patient responded positively to immune therapy. Conclusion: This case highlights challenges in diagnosing immune-mediated myopathy, especially in older patients with atypical presentations. Testing for HMGCR antibodies can aid in diagnosis, particularly when inflammatory markers are absent. Awareness of red flags, such as delayed symptom onset and response to prednisone, is crucial for accurate diagnosis and management.
[Statin-associated muscle symptoms : performance and quality of life]

Paul Peyrel,Pascale Mauriège,Jérôme Frenette,Jean Bergeron,Denis R Joanisse

DOI: https://doi.org/10.53738/REVMED.2024.20.889.1772

2024-10-02

Abstract:Statins use is linked to side effects, notably muscular ones, known as Statin-Associated Muscle Symptoms (SAMS). These can include a pain, an increased sensitivity to palpation, aches, and cramps. SAMS are a real problem in the clinical management of patients, as it is difficult to causally link these complaints with drug use, and they may lead to a reduction in statin intake, or even to the patient -discontinuing their use. The absence of objective markers and the -variety of possible clinical manifestations of these muscular -complaints impede a full understanding of the objective and -subjective impacts of these symptoms on the everyday life of sympto-matic patients. This article assess the current state of knowledge on the impact of SAMS on performance and health--related quality of life.
Who should receive a statin these days? Lessons from recent clinical trials

J Shepherd

DOI: https://doi.org/10.1111/j.1365-2796.2006.01700.x

Abstract:The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are the most successful cardiovascular drugs of all time. By interrupting cholesterol synthesis in the liver, they activate hepatocyte low-density lipoprotein (LDL) receptors and produce consistent and predictable reductions in circulating LDL cholesterol with resulting reproducible improvements in cardiovascular risk by retarding or even regressing the march of atherosclerosis in all major arterial trees (coronary, cerebral and peripheral). Clinical trials have demonstrated their capacity not only to extend life, but also to improve its quality by retarding the progression of diabetes mellitus and chronic renal disease and by enhancing central and peripheral blood flow. They are amongst the most extensively investigated pharmaceutical agents in current clinical use. In cardiovascular end-point trials they have proven ability to help prevent that first and all important myocardial infarction and to reduce the likelihood of a recurrence in those who do succumb. They are equally effective in men and women of all ages and at all levels of cardiovascular risk, whether caused by hypercholesterolaemia, hypertension, cigarette smoking, diabetes mellitus or the metabolic syndrome. In addition, they improve the outlook of patients with familial hypercholesterolaemia whose LDL receptor function is deficient or defective; and all of this comes at minimal risk to the recipient. Their most important potential side effect is myopathy, which on very rare occasions may lead to rhabdomyolysis. Clinical experience shows that myopathic symptoms with creatine kinase levels raised to more than 10 times the upper limit of normal is seen in <0.01% of recipients and progression to fatal rhabdomyolysis because of renal failure has been recorded in only 0.15 cases per million prescriptions. Liver function abnormalities are also, rarely, seen. Again, the frequency of raised aspartate or alanine aminotransferase to more than three times the normal limit is encountered in no more than 1-2% of all treated patients and is completely reversible upon withdrawal of treatment. Progression to hepatitis or liver failure does not occur. This constellation of benefits with little side effect penalty has resulted in the comparison of statins with antibiotics in the global battle against cardiovascular disease.
Association Between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: a Meta-Analysis

Qian Xiang,Shu-qing Chen,Ling-yue Ma,Kun Hu,Zhuo Zhang,Guang-yan Mu,Qiu-fen Xie,Xiao-dan Zhang,Yi-min Cui

DOI: https://doi.org/10.1038/s41397-018-0054-0

2018-01-01

Abstract:Numerous studies have illustrated the relationship between SLCO1B1 T521C polymorphism and statin-induced myopathy risk; however, this association is not consistent. Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from inception to October 2017 to identify potential studies. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from different genetic models by using a random-effects model. Fourteen studies comprising 3265 myopathy patients and 7743 controls were included. The summary ORs suggested that 521CC (OR: 2.31; 95% CI: 1.15–4.63; P = 0.019), 521TC (OR: 1.34; 95% CI: 1.02–1.76; P = 0.034), and 521CC + TC (OR: 1.82; 95% CI: 1.32–2.51; P < 0.001) were associated with a greater risk of statin-induced myopathy than 521TT. The higher incidence of statin-induced myopathy was found to be significantly correlated with the C allele compared with the T allele (OR: 1.89; 95% CI: 1.36–2.62; P < 0.001). In addition, we observed that 521CC + TC was associated with an increased risk of myopathy in individuals who received simvastatin (OR: 2.35; 95% CI: 1.08–5.12; P = 0.032) or rosuvastatin (OR: 1.69; 95% CI: 1.07–2.67; P = 0.024) when compared with 521TT. The 521C allele was associated with a greater risk of cerivastatin-induced myopathy than the T allele (OR: 1.95; 95% CI: 1.47–2.57; P < 0.001). The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin. Future studies should be conducted in subjects receiving specific types of drugs, and any potential adverse events need to be explored.
Incidence of statin-associated muscle symptoms in patients taking statins with RYR1 or CACNA1S variants

Natasha J Petry,Amanda Massmann,Megan Bell,April Schultz,Joel Van Heukelom

DOI: https://doi.org/10.1080/17410541.2024.2342223

Abstract:Background: Statins are commonly used medications. Variants in SLCO1B1, CYP2C9, and ABCG2 are known predictors of muscle effects when taking statins. More exploratory genes include RYR1 and CACNA1S, which can also be associated with disease conditions. Methods: Patients with pathogenic/likely pathogenic variants in RYR1 or CACNA1S were identified through an elective genomic testing program. Through chart review, patients with a history of statin use were assessed for statin-associated muscle symptoms (SAMS) along with collection of demographics and other known risk factors for SAMS. Results: Of the 23 patients who had a pathogenic or likely pathogenic RYR1 or CACNA1S variant found, 12 had previous statin use; of these, SAMS were identified in four patients. Conclusion: These data contribute to previous literature suggesting patients with RYR1 variants may have an increased SAMS risk. Additional research will be helpful in further investigating this relationship and providing recommendations.
Is there value in liver function test and creatine phosphokinase monitoring with statin use?

Allan D Sniderman

DOI: https://doi.org/10.1016/j.amjcard.2004.07.052

2004-11-04

Abstract:Statins have transformed the care of patients with vascular disease. Patients in almost every category that has been studied have benefited substantially. On the other hand, although the incidence of side effects is remarkably low, statins, like any other therapy, are not entirely free of serious risks. From the outset, based on the mechanism of action of statins, hepatotoxicity has been a concern. Moreover, although the mechanisms remain obscure, significant skeletal muscle injury, which can lead to renal failure and death, unquestionably does occur. To mitigate these risks, screening and monitoring programs for hepatic and skeletal muscle injury were put in place when statins were introduced into clinical practice. This article reviews the benefits and the costs of these efforts. Although the benefits have not been shown, the costs are real and substantial. These include the harm caused by inappropriate withdrawal of therapy, which has been shown to be life-saving, as well as the considerable financial expenditure. The conclusion that follows, based on the evidence in hand, is that although these programs were appropriate at the time statins were introduced, they are not appropriate now.
Lipid-lowering approaches to manage statin-intolerant patients

Massimiliano Ruscica,Alessandra Bertoletti,Cecilia Gobbi,Cesare R Sirtori,Stefano Carugo,Alberto Corsini

DOI: https://doi.org/10.1093/eurheartjsupp/suae007

2024-04-01

European Heart Journal Supplements

Abstract:Abstract Statins have improved the potential to prevent cardiovascular disease events and to prolong the lives of patients. Statins, among the most widely used drugs worldwide, reduce the levels of low-density lipoprotein cholesterol (LDL-C) by an average of 30–50%. However, non-adherence to statin therapy, due to statin intolerance, might be as high as 60% after 24 months of treatment and is associated with a 70% increase in the risk of cardiovascular disease events. Statin intolerance can be classified as a complete inability to tolerate any dose of a statin or a partial intolerance with the inability to tolerate the dose necessary to achieve the patient-specific therapeutic objective. Reasons for discontinuation are many, with statin-associated muscle symptoms being cited as the most frequent reason for stopping therapy and the incidence of muscle symptoms increasing with treatment intensity. Considering the causal effect of LDL-C in the atherosclerotic process, clinicians should consider that regardless of the lipid-lowering drugs patients are willing to take, any reduction in LDL-C they achieve will afford them some benefit in reducing cardiovascular risk. Besides statins, the current therapeutic armamentarium offers different strategies to reach LDL-C targets in statin-intolerant patients (i.e. a fixed combination between a lower dose of statin plus ezetimibe, bempedoic acid, or proprotein convertase subtilisin/kexin type 9 inhibition).

cardiac & cardiovascular systems
Statin-Associated Muscle Symptoms: Identification and Recommendations for Management

Kevin C. Maki,Carol F. Kirkpatrick,Mary Katherine Cheeley,Terry A. Jacobson

DOI: https://doi.org/10.1007/s11883-024-01246-y

IF: 5.967

2024-11-25

Current Atherosclerosis Reports

Abstract:Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.

peripheral vascular disease

Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry

Condensation and salt-induced decondensation of DNA upon incorporation of a V-shaped luminescent [Ru2(bpy)4(mbpibH2)](4+).

Color-dependent motion illusions in stationary images and their phenomenal dimorphism.

Statin-associated myasthenic weakness

[The Clinical and Muscular Pathological Features of Statin-Induced Myopathy].

[Jaw orthodontic treatment from view point of the patient and parents].

[On the diagnosis of renovascular hypertonia].

Narrative Review: Statin-Related Myopathy

Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness

Seizures in relation to head injury.

The Role of Mitochondria in Statin-Induced Myopathy

[Etiology and pathogenesis of primary hydrocele in children].

Plasma statin concentrations do not correlate with statin-induced myalgia

Anti-HMGCR myopathy mimicking facioscapulohumeral muscular dystrophy

[Statin-associated muscle symptoms : performance and quality of life]

Who should receive a statin these days? Lessons from recent clinical trials

Association Between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: a Meta-Analysis

Incidence of statin-associated muscle symptoms in patients taking statins with RYR1 or CACNA1S variants

Is there value in liver function test and creatine phosphokinase monitoring with statin use?

Lipid-lowering approaches to manage statin-intolerant patients

Statin-Associated Muscle Symptoms: Identification and Recommendations for Management